Amgen disses drug pricing bill, while amping $4B rare drug company deal and upcoming Humira biosim launch
Add Amgen CEO Bob Bradway to the chorus of pharma CEOs lamenting the pending drug pricing legislation in the US Senate.
“For some time, we’ve been advocating for reforms that respect innovation and provide improved access to it. The proposed bill does neither. The bill will impose price controls, and price controls will stymie innovation … When it comes to innovation and affordability, this bill is a lose-lose for patients,” Bradway said in his opening remarks during Amgen’s Q2 earnings call on Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.